文献速递儿科与产科急症消化、代谢与肾脏急症

≤90天发热婴儿COVID-19检测阳性时侵袭性细菌感染患病率:系统评价与Meta分析

Prevalence of invasive bacterial infection in febrile infants ≤90 days with a COVID-19 positive test: a systematic review and meta-analysis.
PubMed 文献 · Emerg Med J · 2024-03-21
一句话结论≤90天发热婴儿SARS-CoV-2阳性者IBI合并患病率0.14%,>28天者更低,作者提示该亚组可不行血液检查。

该系统评价与Meta分析检索2020年2月至2023年5月多个数据库,纳入33项研究、3943例≤90天发热且SARS-CoV-2抗原/PCR阳性并完成血或脑脊液培养的婴儿。IBI(血和/或脑脊液检出病原细菌)合并患病率为0.14%(95%CI 0.02%~0.27%);0-21天为0.56%(95%CI 0.0%~1.27%),22-28天为0.53%(95%CI 0.0%~1.22%),29-60天为0.11%(95%CI 0.0%~0.24%)。作者认为COVID-19阳性发热婴儿IBI风险低,尤其>28天者,提示该亚组可不行血液检查。

要点

  • ≤90天发热且SARS-CoV-2阳性的婴儿,IBI合并患病率仅0.14%(95%CI 0.02%~0.27%)。
  • 按年龄分层:0-21天IBI患病率0.56%(95%CI 0.0%~1.27%),22-28天0.53%(95%CI 0.0%~1.22%)。
  • 29-60天IBI患病率降至0.11%(95%CI 0.0%~0.24%)。
  • 作者认为COVID-19阳性发热婴儿IBI风险低,尤其>28天者,提示该亚组可不行血液检查。

适用人群与场景

  • ≤90天龄、有发热、SARS-CoV-2抗原试验或PCR检测阳性,且完成血培养或脑脊液培养的婴儿。
  • 排除:病例报告患者数<3例、非英语/法语/西班牙语文章、社论及其他叙述性研究。

诊断标准与关键阈值

  • IBI定义:血液和/或脑脊液(CSF)中检出病原细菌。

研究设计与关键结果

  • 系统评价与Meta分析,检索MEDLINE、Embase、Cochrane Central Register、Web of Science、ClinicalTrials.gov及灰色文献,时间2020年2月至2023年5月。
  • 共检索到1023项研究,最终33项纳入Meta分析,报告3943例COVID-19阳性发热婴儿并获得血或脑脊液培养。
  • IBI合并患病率0.14%(95%CI 0.02%~0.27%)。
  • 按年龄:0-21天IBI患病率0.56%(95%CI 0.0%~1.27%),22-28天0.53%(95%CI 0.0%~1.22%),29-60天0.11%(95%CI 0.0%~0.24%)。
  • 采用随机效应模型合并数据;研究零事件时加固定连续性校正0.01;采用美国国立卫生研究院质量评估工具评价研究质量。

证据类型、等级与局限

  • 证据类型:系统评价与Meta分析,遵循PRISMA指南,PROSPERO注册号CRD42022356507。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为COVID-19阳性发热婴儿≤90天龄IBI风险低,尤其>28天龄者,提示该亚组可不行血液检查。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Febrile infants with an infection by influenza or enterovirus are at low risk of invasive bacterial infection (IBI).

OBJECTIVE: To determine the prevalence of IBI among febrile infants ≤90 days old with a positive COVID-19 test.

METHODS: MEDLINE, Embase, Cochrane Central Register databases, Web of Science, ClinicalTrials.gov and grey literature were searched for articles published from February 2020 to May 2023.

INCLUSION CRITERIA: researches reporting on infants ≤90 days of age with fever and a positive test for SARS-CoV-2 (antigen test/PCR). Case reports with <3 patients, articles written in a language other than English, French or Spanish, editorials and other narrative studies were excluded. Preferred Reposting Items for Systematic Reviews and Meta-analysis guidelines were followed, and the National Institutes of Health Quality Assessment Tool was used to assess study quality. The main outcome was the prevalence of IBI (a pathogen bacterium identified in blood and/or cerebrospinal fluid (CSF)). Forest plots of prevalence estimates were constructed for each study. Heterogeneity was assessed and data were pooled by meta-analysis using a random effects model. A fixed continuity correction of 0.01 was added when a study had zero events.

RESULTS: From the 1023 studies and 3 databases provided by the literature search, 33 were included in the meta-analysis, reporting 3943 febrile infants with a COVID-19 positive test and blood or CSF culture obtained. The pooled prevalence of IBI was 0.14% (95% CI, 0.02% to 0.27%). By age, the prevalence of IBI was 0.56% (95% CI, 0.0% to 1.27%) in those 0-21 days old, 0.53% (95% CI, 0.0% to 1.22%) in those 22-28 days old and 0.11% (95% CI, 0.0% to 0.24%) in those 29-60 days old.

CONCLUSION: COVID-19-positive febrile infants ≤90 days old are at low risk of IBI, especially infants >28 days old, suggesting this subgroup of patients can be managed without blood tests.

PROSPERO REGISTRATION NUMBER: CRD42022356507.

来源:Emerg Med J,查看原文。版权归原作者所有。

参考来源

  1. Pérez-Porra S, Granda E, Benito H, et al. Prevalence of invasive bacterial infection in febrile infants ≤90 days with a COVID-19 positive test: a systematic review and meta-analysis. Emerg Med J. 2024. PMID: 38071527. doi:10.1136/emermed-2023-213483

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。